Prophylaxis against pcp remains the single most cost-effective intervention in HIV+ patients at risk. But treatment has, in some ways, become a moving target in some patients, as their CD4 count rises and falls with newer HIV therapies, medication side effects, and variable compliance.
Microbicide research suffered a setback earlier this year when a phase III clinical trial studying cellulose sulfate to block HIV infection was stopped prematurely because there appeared to be a higher rate of HIV infections among the study group than the control group.
A recent study suggests that emergency medicine patients may not have a high level of acceptance of the practice of providing an exemption to informed consent for research involving emergency medical settings.
The Seattle hospital that performed growth attenuation treatments and surgery on the severely disabled child known as "Ashley" took place in violation of Washington state law, but the hospital stands behind the ethics and best-interest issues that resulted in the treatment.